ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Wegener’s granulomatosis"

  • Abstract Number: 748 • 2013 ACR/ARHP Annual Meeting

    Efficacy Of Methotrexate For Remission Induction and Maintenance In Granulomatosis With Polyangiitis In Routine Clinical Practice

    Megan L. Krause1, Misbah Baqir2, Rodrigo Cartin-Ceba3, Tobias Peikert4, Karina Keogh4 and Ulrich Specks4, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Pulmonary/Critical Care, Mayo Clinic, Rochester, MN, 3Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, 4Mayo Clinic, Rochester, MN

    Background/Purpose: Methotrexate has been shown to be effective for both induction (non-severe disease) and maintenance of remission in patients with Granulomatosis with Polyangiitis (GPA) in…
  • Abstract Number: 739 • 2013 ACR/ARHP Annual Meeting

    Cardiac Involvement In Granulomatosis With Polyangiitis

    Lucy McGeoch1, Simon Carette2, David Cuthberston3, Gary S. Hoffman4, Nader A. Khalidi5, Curry L Koening6, Carol A. Langford7, Paul A. Monach8, Larry W. Moreland9, Philip Seo10, Ulrich Specks11, Steven R. Ytterberg12, Carol McAlear13, Peter A Merkel14, Christian Pagnoux2 and The Vcrc15, 1Vasculitis clinic, Division of rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 3Biostatistics, University of South Florida, Tampa, FL, 4Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 5Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, 6Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, 7Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 8Rheumatology, Boston University, Boston, MA, 9Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 10Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 11Mayo Clinic, Rochester, MN, 12Rheumatology Division, Mayo Clinic, Rochester, MN, 13University of Pennsylvania, Philadelphia, PA, 14Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 15University of Pennsylvania and VA Medical Center, Philadelphia, PA

    Background/Purpose: Prior cohort studies in Europe have found cardiac involvement to be rare in granulomatosis with polyangiitis (GPA) but associated with significant increases in mortality…
  • Abstract Number: 743 • 2013 ACR/ARHP Annual Meeting

    Efficacy Of Rituximab For Otolaryngologic (ENT) Manifestations Of Granulomatosis With Polyangiitis (GPA, Wegener’s granulomatosis)

    Lindsay Lally1, Robert Lebovics2, Wei-Ti Huang3 and Robert F. Spiera1, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Otolaryngology, St. Luke's-Roosevelt Hospital Center, New York, NY, 3Biostatistics, Hospital for Special Surgery, New York, NY

    Background/Purpose: ENT involvement is the most prevalent manifestation of GPA.  Rituximab (RTX) is a proven effective remission induction therapy for severe GPA with vasculitic manifestations. …
  • Abstract Number: 2596 • 2012 ACR/ARHP Annual Meeting

    Rituximab Treatment for Antineutrophil Cytoplasmic Antibody – Associated Vasculitis in Children

    Katharine F. Moore1, Leonard L. Dragone2, Jennifer B. Soep3 and J. Roger Hollister4, 1Pediatric Rheumatology, Seattle Children's Hospital / University of Washington, Seattle, WA, 2Dept of Pediatrics, National Jewish Health, Denver, CO, 3Pediatric Rheumatology, Children's Hospital Colorado, Aurora, CO, 4Dept of Pediatrics, Children's Hospital Colorado, Aurora, CO

    Background/Purpose: The purpose of this study was to report the experience of a tertiary-care children’s hospital using rituximab in the treatment of pediatric antineutrophil cytoplasmic…
  • Abstract Number: 2564 • 2012 ACR/ARHP Annual Meeting

    A Risk Score for Predicting Short-Term Incidence of Death or Relapse in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    Carla Maldini1, Matthieu Resche-Rigon2, David Jayne3, Kerstin Westman4 and Alfred Mahr1, 1Internal Medicine, Hospital Saint-Louis, Paris, France, 2Biostatistics, Hopital Saint-Louis, Paris, France, 3Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, 4Nephrology and Transplantation, Skåne University Hospital Malmö, Lund University, Malmö, Sweden

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), combining granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), is associated with a substantial risk of relapse or…
  • Abstract Number: 2393 • 2012 ACR/ARHP Annual Meeting

    High Mobility Group Box 1 Levels Are Not Associated with Subclinical Carotid Atherosclerosis in Patients with Granulomatosis with Polyangiitis but Are Reduced by Glucocorticoids and Statins

    Alexandre Wagner S. de Souza1, Karina de Leeuw2, Johanna Westra2, Andries J. Smit3, Anne Marijn van der Graaf2, Hans L. A. Nienhuis1, Johan Bijzet2, Pieter C. Limburg4, Coen A. Stegeman5, Marc Bijl6 and Cees G.M. Kallenberg2, 1Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 3Vascular Diseases, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 4Department of Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, 5Nephrology, University Medical Center Groningen, Groningen, Netherlands, 6Rheumatology and Clinical Immunology, Martini Hospital, Groningen, Netherlands

    Background/Purpose: High mobility group box 1 (HMGB1) is a non-histone DNA binding protein that is passively released by dying cells or actively secreted by immunocompetent…
  • Abstract Number: 2397 • 2012 ACR/ARHP Annual Meeting

    Urinary Biomarkers in Vasculitis Associated with Anti-Neutrophil Cytoplasmic Antibodies

    Jason G. Lieberthal1, David Cuthbertson2, Simon Carette3, Gary S. Hoffman4, Nader A. Khalidi5, Curry L. Koening6, Carol A. Langford7, Kathleen Maksimowicz-McKinnon8, Philip Seo9, Ulrich Specks10, Steven R. Ytterberg11, Peter A. Merkel12 and Paul A. Monach13, 1Medicine, Boston University School of Medicine, Boston, MA, 2Department of Biostatistics, University of South Florida, Tampa, FL, 3Div of Rheum/E1-422, UHN/MSH, Toronto, ON, Canada, 4Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, 5Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, 6Internal Medicine, Salt Lake City Veterans Administration, Salt Lake City, UT, 7Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 8Rheumatology, University of Pittsburgh, Pittsburgh, PA, 9Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 10Mayo Clinic, Rochester, MN, 11Rheumatology Division, Mayo Clinic, Rochester, MN, 12University of Pennsylvania, Philadelphia, PA, 13Rheumatology, Boston University, Boston, MA

    Background/Purpose:   Glomerulonephritis is common in ANCA-associated vasculitis (AAV), but non-invasive tools for early detection of renal involvement suffer from low sensitivity (red blood cell…
  • Abstract Number: 1653 • 2012 ACR/ARHP Annual Meeting

    Outcomes in Patients with Granulomatosis with Polyangiitis (Wegener’s) Treated with Short- Vs. Long-Term Maintenance Therapy

    Jason Springer1, Benjamin Nutter2, Carol A. Langford3, Gary S. Hoffman4 and Alexandra Villa-Forte5, 1Dept of Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, 2Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, 3Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 4Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 5Rheumatology, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Disease remission can be successfully achieved in the majority of patients (pts) with Granulomatosis with polyangiitis (Wegener’s) (GPA).  After remission (rem) is achieved continued…
  • Abstract Number: 1655 • 2012 ACR/ARHP Annual Meeting

    An Open-Label Trial of Abatacept in Mild Relapsing Granulomatosis with Polyangiitis (Wegener’s)

    Carol A. Langford1, David Cuthbertson2, Gary S. Hoffman3, Jeffrey Krischer4, Carol McAlear5, Paul A. Monach6, Philip Seo7, Ulrich Specks8, Steven R. Ytterberg9, Peter A. Merkel5 and for the Vasculitis Clinical Research Consortium5, 1Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 2Department of Biostatistics, University of South Florida, Tampa, FL, 3Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, 4University of South Florida, Tampa, FL, 5University of Pennsylvania, Philadelphia, PA, 6Rheumatology, Boston University, Boston, MA, 7Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 8Mayo Clinic, Rochester, MN, 9Rheumatology Division, Mayo Clinic, Rochester, MN

    Background/Purpose: Granulomatosis with polyangiitis (Wegener's, GPA) is a primary systemic vasculitis that carries a high predilection for relapse. An area of unmet need has been…
  • Abstract Number: 1537 • 2012 ACR/ARHP Annual Meeting

    Pathogenesis of Atherosclerosis in   Granulomatosis Polyangiitis

    Rula Hajj-Ali1, Roy L. Silverstein2, Gary S. Hoffman3 and Carol A. Langford4, 1Cleveland Clinic Foundation, Cleveland, OH, 2Blood Research Institute, Medical College of Wisconsin, Milwaukee, WI, 3Rheumatic & Immunologic Dis, Cleveland Clinic Found A50, Cleveland, OH, 4Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Previous studies from our group suggested that the inflammatory events that occur during relapses in patients with Granulomatosis with Polyangiitis (GPA, Wegener’s) may have…
  • Abstract Number: 1540 • 2012 ACR/ARHP Annual Meeting

    Practice Patterns in the Treatment of ANCA-Associated Vasculitis: Exploring Differences Among Subspecialties At a Single Academic Medical Center

    Lindsy J. Forbess1, Kenneth W. Griffin2 and Robert F. Spiera3, 1Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 2Public Health, Weill Cornell Medical College, New York, NY, 3Rheumatology, Hospital for Special Surgery, New York, NY

    Background/Purpose: Randomized controlled trial evidence helps guide physician treatment choices for ANCA-Associated Vasculitis (AAV). Data for remission maintenance therapy following rituximab (RTX) in generalized disease,…
  • Abstract Number: 1527 • 2012 ACR/ARHP Annual Meeting

    Patient Global Assessments for Disease Activity Are Predictive of Future Flare in Granulomatosis with Polyangiitis (Wegener’s)

    Gunnar Tomasson1, John C. Davis Jr.2, Gary S. Hoffman3, W. Joseph McCune4, Ulrich Specks5, Robert F. Spiera6, E. William St. Clair7, John H. Stone8 and Peter A. Merkel9, 1Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland, 2Genentech, Inc, South San Francisco, CA, 3Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, 4Int Med/ Rheum, University of Michigan, Ann Arbor, MI, 5Mayo Clinic, Rochester, MN, 6Rheumatology, Hospital for Special Surgery, New York, NY, 7Medicine, Duke University Medical Center, Durham, NC, 8Rheumatology, Massachusetts General Hospital, Boston, MA, 9University of Pennsylvania, Philadelphia, PA

    Background/Purpose:  In granulomatosis with polyangiitis GPA), disease activity is assessed by physician-based measures. In some other rheumatic diseases, such as rheumatoid arthritis (RA) and ankylosing…
  • Abstract Number: 1530 • 2012 ACR/ARHP Annual Meeting

    Plasma Cell Analysis As a Biomarker for Disease Activity in Patients with Granulomatosis with Polyangiitis

    Bimba F. Hoyer1, Adriano Taddeo2, Maika Rothkegel2, Gerd Burmester3, Andreas H. Radbruch2 and Falk Hiepe4, 1Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, 2Deutsches Rheumaforschungszentrum, Berlin, Germany, 3Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, 4Med. Klinik m. Sp. Rheumatologie und klin. Immunologie, Charité University Hospital Berlin, Berlin, Germany

    Background/Purpose: B cells are thought to play an important role in granulomatosis with polyangiitis (GPA) due to the presence of autoantibodies reacting with specific neutrophil…
  • Abstract Number: 1534 • 2012 ACR/ARHP Annual Meeting

    IgG4 Plasma Cell Infiltration in Granulomatosis with Polyangiitis (formerly Wegener’s) Lung Biopsies

    Mollie Carruthers1, Shweta Shinagare2, Arezou Khosroshahi1, Vikram Deshpande2 and John H. Stone1, 1Rheumatology, Massachusetts General Hospital, Boston, MA, 2Pathology, Massachusetts General Hospital, Boston, MA

    Background/Purpose: Granulomatosis with polyangiitis (GPA) and IgG4-related disease (IgG4-RD) are both immune-mediated conditions that can involve multiple organ systems. In GPA, IgG4-positive plasma cell infiltration…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology